Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Verve Therapeutics Inc (NQ: VERV )

5.590 +0.260 (+4.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,241,117
Open 5.580
Bid (Size) 5.480 (50)
Ask (Size) 5.580 (1)
Prev. Close 5.330
Today's Range 5.500 - 5.790
52wk Range 4.900 - 21.42
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a... 
Via Benzinga
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
Via Benzinga

Performance

YTD
-60.07%
-60.07%
1 Month
-10.13%
-10.13%
3 Month
-61.02%
-61.02%
6 Month
-58.00%
-58.00%
1 Year
-69.15%
-69.15%

More News

Read More
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
After a Serious Setback, Is Verve Therapeutics a Buy?
Via The Motley Fool
Verve Therapeutics Announces Leadership Update
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
Via Benzinga
Topics ETFs
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
Via InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
Via InvestorPlace
VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Via Benzinga
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
Via Benzinga
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
Via Benzinga
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Stumbles, Heads For Worst Day Since February
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Via Benzinga
Crude Oil Surges Over 1%; US Factory Orders Increase In February
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.